SK
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
4
6 agencies contacted
Activity
filings by quarter
Works on
Specific issues
GLP-1 pricing and licensing, Medical Innovation Act, Medicare drug price negotiation implementation, Medicines for All Act, pharmaceutical manufacturer-sponsored telehealth platforms, S.2140 PERA, S.2220 PREVAIL Act, S.Res.684 supporting GAVI; PILLS Act, H.R.885, S.315 TRACK Act, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, S.2044 End Price Gouging for Medications Act, S.2140 PERA; S.2220 PREVAIL Act; S. 79, Interagency Patent Coordination and Improvement Act; S. 142, Preserve Access to Affordable Generics and Biosimilars Act; S. 148, Stop STALLING Act; S. 150, Affordable Prescriptions for Patients Act, We PAID Act; march-in rights, S.2140 PERA; S.2220 PREVAIL Act, intramural access plan and licensing policy, march-in rights guidance.
government support for flu vaccine development, government use patent licensing; S.954 Affordable Insulin Now Act, march-in rights; S.954, Medicare drug price negotiation and inflationary rebate expansion, pharmacy benefit managers; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, vaccine disinformation, weight loss drug pricing, DTC pharmaceutical advertising, Medicare drug price negotiation and inflationary rebate expansion; government use patent licensing; march-in rights; reasonable pricing and access conditions, S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150 Affordable Prescriptions for Patients Act, GLP-1 pricing and licensing, DOD prescription drug international reference pricing; misleading social media prescription drug promotion penalties, social media prescription drug promotion harms, Improving Medicare Coverage Act.
Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing.
march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.